{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:19:27Z","timestamp":1765808367339,"version":"3.37.3"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T00:00:00Z","timestamp":1717027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clml.2024.05.022","type":"journal-article","created":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T01:08:56Z","timestamp":1717204136000},"page":"e344-e349","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0096-3826","authenticated-orcid":false,"given":"Aroog","family":"Khaliq","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-0512","authenticated-orcid":false,"given":"William","family":"Wesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emerson","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1747-1404","authenticated-orcid":false,"given":"Carine","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8122-0563","authenticated-orcid":false,"given":"Muhammad Umair","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tara","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-6307","authenticated-orcid":false,"given":"Joaquina","family":"Baranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.022_bib0001","unstructured":"Association of American Medical Colleges. Physician specialty data report [internet]. 2022. Available from: https:\/\/www.aamc.org\/data-reports\/workforce\/report\/physician-specialty-data-report."},{"issue":"9","key":"10.1016\/j.clml.2024.05.022_bib0002","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/onco.13871","article-title":"The matilda effect: Underrecognition of women in hematology and oncology awards","volume":"26","author":"Patel","year":"2021","journal-title":"Oncologist"},{"issue":"24","key":"10.1016\/j.clml.2024.05.022_bib0003","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1182\/bloodadvances.2022008120","article-title":"Gender and early-career faculty disparities in hematology and oncology board review lecture series","volume":"6","author":"Syaj","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.05.022_bib0004","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1200\/OP.19.00255","article-title":"Gender differences in faculty rank and leadership positions among hematologists and oncologists in the United States","volume":"16","author":"Riaz","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.clml.2024.05.022_bib0005","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1097\/HMR.0000000000000290","article-title":"The gender pay gap in medicine: a systematic review","volume":"46","author":"Hoff","year":"2021","journal-title":"Health Care Manage Rev"},{"issue":"10401","key":"10.1016\/j.clml.2024.05.022_bib0006","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(23)01428-9","article-title":"Author gender representation of journal reviews and editorials on lymphoma (2017-22)","volume":"402","author":"Hawkes","year":"2023","journal-title":"Lancet North Am Ed"},{"issue":"3","key":"10.1016\/j.clml.2024.05.022_bib0007","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/jha2.470","article-title":"Gender disparities in multiple myeloma publications","volume":"3","author":"Dweik","year":"2022","journal-title":"eJHaem"},{"issue":"26","key":"10.1016\/j.clml.2024.05.022_bib0008","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2024.05.022_bib0009","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.05.022_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.05.022_bib0011","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.clml.2024.05.022_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet North Am Ed"},{"issue":"8","key":"10.1016\/j.clml.2024.05.022_bib0013","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.clml.2024.05.022_bib0014","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet North Am Ed"},{"issue":"10297","key":"10.1016\/j.clml.2024.05.022_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet North Am Ed"},{"issue":"2","key":"10.1016\/j.clml.2024.05.022_bib0016","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2024.05.022_bib0017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.05.022_bib0018","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-Cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.clml.2024.05.022_bib0019","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet North Am Ed"},{"issue":"8","key":"10.1016\/j.clml.2024.05.022_bib0020","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(22)00339-4","article-title":"Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study","volume":"23","author":"Sehgal","year":"2022","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.05.022_bib0021","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.05.022_bib0022","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.clml.2024.05.022_bib0023","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1080\/10428194.2022.2038378","article-title":"Gender disparities in the national institutes of health funding for hematologic malignancies and cellular therapies","volume":"63","author":"Siddiqui","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.022_bib0024","doi-asserted-by":"crossref","unstructured":"Shruti R Patel, Ivy Riano, Inas Abuali, et al. Race\/ethnicity and gender representation in hematology and oncology editorial boards: what is the state of diversity?, Oncologist, Volume 28, Issue 7, July, Pages 609-617, https:\/\/doi.org\/10.1093\/oncolo\/oyad103.","DOI":"10.1093\/oncolo\/oyad103"},{"issue":"7","key":"10.1016\/j.clml.2024.05.022_bib0025","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1080\/10428194.2022.2038378","article-title":"Gender disparities in the national institutes of health funding for hematologic malignancies and cellular therapies","volume":"63","author":"Siddiqui","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.022_bib0026","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2024.05.022_bib0027","unstructured":"Drug Approvals and Databases. U.S. food and drug administration. Updated August 08, 2022. Accessed March 30, 2024. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/drug-approvals-and-databases."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T15:10:45Z","timestamp":1729696245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2152265024002234"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}